Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Bipolar disorder is a leading cause of disability worldwide. A high proportion of patients
with bipolar disorder experience persistent depressive symptoms that do not respond to
standard drug treatments. Recent evidence has suggested that anti-inflammatory treatment may
reduce depressive symptoms. Minocycline is a tetracycline antibiotic with good central
nervous system (CNS) penetration that has been suggested to be effective as an adjunct drug
in improving depressive symptoms. Celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor,
has also shown promising results in the treatment of depressive symptoms. In this factorial
design, double blind, randomised controlled trial the investigators will determine the
efficacy of minocycline and/or celecoxib as an adjunct to treatment as usual (TAU) in
patients experiencing a depressive phase of bipolar I or II disorder. The investigators
hypothesise that augmentation with minocycline and/or celecoxib will lead to an improvement
in depressive symptoms in participants in comparison with placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Pakistan Institute of Learning and Living Pakistan Institute of Living and Learning
Collaborators:
Abbasi Shaheed Hospital Dow University of Health Sciences Rawalpindi Medical College, Pakistan Stanley Medical Research Institute University of Manchester